AstraZeneca Reports the US FDA Acceptance of NDA and Granted Priority Review of Capivasertib + Faslodex (fulvestrant) for Advanced HR-Positive Breast Cancer
Shots:
- The US FDA has accepted the NDA & granted Priority Review for capivasertib + fulvestrant in adult patients with HR+ HER2- LA or metastatic breast cancer. The US FDA’s decision is expected in Q4’23
- The NDA was based on the P-III trial (CAPItello-291) results presented at SABCS 2022 & published in the NEJM evaluating capivasertib + Faslodex vs PBO + Faslodex in 708 adult patients, showed a 40% reduction in risk of disease progression or death in the overall trial population; m-PFS (7.2 vs 3.6mos.), OS data were immature, early data are encouraging & the safety profile was similar to prior reported trials
- Capivasertib was discovered by AstraZeneca in collaboration with Astex Therapeutics (and its collaboration with ICR & CRT). The company works with the US FDA to bring the therapy to patients shortly
Ref: AstraZeneca | Image: AstraZeneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
